Literature DB >> 11283029

Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.

S J Stevens1, I Pronk, J M Middeldorp.   

Abstract

Epstein-Barr virus (EBV) DNA load monitoring in peripheral blood has been shown to be a useful tool for the diagnosis of aberrant EBV infections. In the present study we compared the relative diagnostic values of EBV DNA load monitoring in unfractionated whole blood and simultaneously obtained serum or plasma samples from Burkitt's lymphoma (BL) patients, transplant recipients, human immunodeficiency virus (HIV)-infected individuals, and infectious mononucleosis (IM) patients by a quantitative competitive PCR (Q-PCR). The EBV DNA load in BL patients was mainly situated in the cellular blood compartment (up to 4.5 x 10(6) copies/ml). EBV DNA loads in unfractionated whole blood and parallel serum samples showed no correlation. In transplant recipients, IM patients, and HIV-infected patients, the EBV burden in the circulation was almost exclusively restricted to the cellular blood compartment, because serum or plasma samples from these patients yielded negative results by Q-PCR, despite high viral loads in corresponding whole-blood samples. A 10-fold more sensitive but qualitative BamHI-W-repeat PCR occasionally revealed the presence of EBV at <2,000 copies of EBV DNA per ml of serum. Spiking of 100 copies of EBV DNA in samples with negative Q-PCR results excluded the presence of inhibitory factors in serum or plasma that influenced the Q-PCR result. Serum samples from all populations were often positive for beta-globin DNA, indicating cell damage in vivo or during serum preparation. We conclude that serum is an undesirable clinical specimen for EBV DNA load monitoring because it omits the presence of cell-associated virus and uncontrolled cell lysis may give irreproducible results or overestimation of the DNA load. Unfractionated whole blood is strongly preferred since it combines all blood compartments that may harbor EBV and it best reflects the absolute viral burden in the patient's circulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283029      PMCID: PMC87912          DOI: 10.1128/JCM.39.4.1211-1216.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Development of a real-time quantitative assay for detection of Epstein-Barr virus.

Authors:  H G Niesters; J van Esser; E Fries; K C Wolthers; J Cornelissen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Epstein-Barr virus: Co-opting B-cell memory and migration.

Authors:  A B Rickinson; P J Lane
Journal:  Curr Biol       Date:  2000-02-10       Impact factor: 10.834

3.  Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma.

Authors:  J H Li; D Huang; B F Sun; X Zhang; J Middeldorp; H Klamut; F F Liu
Journal:  Int J Cancer       Date:  2000-08-15       Impact factor: 7.396

4.  High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders.

Authors:  F Baldanti; P Grossi; M Furione; L Simoncini; A Sarasini; P Comoli; R Maccario; R Fiocchi; G Gerna
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.

Authors:  Y M Lo; L Y Chan; A T Chan; S F Leung; K W Lo; J Zhang; J C Lee; N M Hjelm; P J Johnson; D P Huang
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

6.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Authors:  A Gustafsson; V Levitsky; J Z Zou; T Frisan; T Dalianis; P Ljungman; O Ringden; J Winiarski; I Ernberg; M G Masucci
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

7.  Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer.

Authors:  K Shotelersuk; C Khorprasert; S Sakdikul; W Pornthanakasem; N Voravud; A Mutirangura
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

8.  Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.

Authors:  G Gerna; F Baldanti; D Lilleri; M Parea; E Alessandrino; A Pagani; F Locatelli; J Middeldorp; M G Revello
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

9.  Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.

Authors:  S J Stevens; E A Verschuuren; I Pronk; W van Der Bij; M C Harmsen; T H The; C J Meijer; A J van Den Brule; J M Middeldorp
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

10.  Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.

Authors:  G J Babcock; L L Decker; R B Freeman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more
  39 in total

1.  Solid phase DNA amplification: a simple Monte Carlo Lattice model.

Authors:  Jean-Francois Mercier; Gary W Slater; Pascal Mayer
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

2.  Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma.

Authors:  Erwan Piriou; Amolo S Asito; Peter O Sumba; Nancy Fiore; Jaap M Middeldorp; Ann M Moormann; Robert Ploutz-Snyder; Rosemary Rochford
Journal:  J Infect Dis       Date:  2012-02-01       Impact factor: 5.226

3.  Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation.

Authors:  Rianne Luderer; Marieke Kok; Hubert G M Niesters; Rob Schuurman; Okke de Weerdt; Steven F T Thijsen
Journal:  Mol Diagn       Date:  2005

4.  Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.

Authors:  Katherine D Westmoreland; Nathan D Montgomery; Christopher C Stanley; Nader Kim El-Mallawany; Peter Wasswa; Toon van der Gronde; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Coxcilly Kampani; N George Liomba; Tamiwe Tomoka; Bal M Dhungel; Marcia K Sanders; Robert Krysiak; Peter Kazembe; Dirk P Dittmer; Yuri Fedoriw; Satish Gopal
Journal:  Int J Cancer       Date:  2017-03-24       Impact factor: 7.396

5.  Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms.

Authors:  Samira Fafi-Kremer; Patrice Morand; Come Barranger; Gérard Barguès; Stéphane Magro; Jérôme Bés; Philippe Bourgeois; Martine Joannes; Jean-Marie Seigneurin
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 6.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

7.  Comparison of QIAsymphony automated and QIAamp manual DNA extraction systems for measuring Epstein-Barr virus DNA load in whole blood using real-time PCR.

Authors:  Stella Laus; Lawrence A Kingsley; Michael Green; Robert M Wadowsky
Journal:  J Mol Diagn       Date:  2011-09-01       Impact factor: 5.568

8.  Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Authors:  Sharon D Stoker; Maarten A Wildeman; Zlata Novalic; Renske Fles; Vincent van der Noort; Remco de Bree; Weibel W Braunius; Guido B van den Broek; Bas Kreike; Kenneth W Kross; Hedy Juwana; Octavia Ramayanti; Sandra A W M Verkuijlen; Jan Paul de Boer; Astrid E Greijer; Jaap M Middeldorp; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-01       Impact factor: 2.503

9.  Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Adriaan J C van den Brule; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

10.  Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.

Authors:  Barbara C Gärtner; Hansjörg Schäfer; Katja Marggraff; Günter Eisele; Marco Schäfer; Dagmar Dilloo; Klaus Roemer; Hans-Jürgen Laws; Martina Sester; Urban Sester; Hermann Einsele; Nikolaus Mueller-Lantzsch
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.